As of September 30, 2026, Roivant Sciences Ltd. carries a market capitalization of 23.39B, placing it among publicly traded companies globally. Its enterprise value stands at 23.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 23.39B |
| Enterprise Value | 23.98B |
Roivant Sciences Ltd.'s next confirmed earnings release is scheduled for February 15, 2027.
| Earnings Date | 2/15/2027 |
As of September 30, 2026, Roivant Sciences Ltd. has 723.69M shares outstanding.
| Shares Outstanding | 723.69M |
These figures are as of September 30, 2026.
| PS Ratio | 633.65 |
| P/FCF Ratio | -811.02 |
| P/OCF Ratio | -715.39 |
These figures are as of September 30, 2026. The EV/Sales ratio of 661.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 23.98B versus a market cap of 23.39B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 661.55 |
As of September 30, 2026, Roivant Sciences Ltd. maintains a current ratio of 15.56, meaning it holds 15.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 15.56 |
| Debt / EBITDA | -0.17 |
These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -6.86, reflecting losses generated across the asset base. The company generates approximately 49,772.26 in revenue per employee across its workforce of 728.25, a quick read on workforce productivity versus industry peers.
| Return on Assets (ROA) | -6.86 |
| Revenue Per Employee | 49,772.26 |
| Employee Count | 728.25 |
Over the twelve months ended September 30, 2026, Roivant Sciences Ltd. recorded 92.07M in income tax expense. The company reported a pretax loss of -262.20M and -303.82M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 92.07M |
As of the close on November 17, 2026, Roivant Sciences Ltd.'s stock has gained approximately 98.10% over the past 52 weeks. The 50-day moving average sits at 33.12, while the 200-day moving average is 28.36.
| 52-Week Price Change | 98.10% |
| 50-Day Moving Average | 33.12 |
| 200-Day Moving Average | 28.36 |
Over the twelve months ended September 30, 2026, Roivant Sciences Ltd. generated 36.25M in revenue and converted that into -303.82M in net income, yielding earnings per share of -0.48. EBITDA reached -490.05M, while operating income came in at -1.17B.
| Revenue | 36.25M |
| Gross Profit | 32.14M |
| Operating Income | -1.17B |
| Pretax Income | -262.20M |
| Net Income | -303.82M |
| EBITDA | -490.05M |
| EBIT | -492.28M |
| Earnings Per Share (EPS) | -0.48 |
These figures are as of September 30, 2026.
| Total Debt | 81.87M |
| Working Capital | 3.60B |
Roivant Sciences Ltd. produced -32.11M in operating cash flow over the twelve months ended September 30, 2026. After subtracting 2.69M in capital expenditures, free cash flow totaled -29.42M - equivalent to -0.04 per share.
| Operating Cash Flow | -32.11M |
| Capital Expenditures | 2.69M |
| Free Cash Flow | -29.42M |
| FCF Per Share | -0.04 |
Over the twelve months ended September 30, 2026, Roivant Sciences Ltd. posted a gross margin of 88.68, reflecting its pricing power and cost economics. The operating margin of -3,233.98 and net profit margin of -838.21 provide insight into operational efficiency.
| Gross Margin | 88.68 |
| Operating Margin | -3,233.98 |
| Pretax Margin | -723.38 |
| Profit Margin | -838.21 |
| EBITDA Margin | -1,351.98 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -0.12: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.65, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Roivant Sciences Ltd. shareholders.
| Shareholder Yield | 0.65 |
| FCF Yield | -0.12 |
As of September 30, 2026, Roivant Sciences Ltd. has an Altman Z-Score of 2.98, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.98 |
Already premium?